AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Speaking of the pipeline, Bristol-Myers Squibb has 55 compounds in development. In particular, Cobenfy, a novel treatment for adults with the psychiatric disorder schizophrenia, just received FDA ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY ... from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and trospium chloride) in schizophrenia in adults ...